CIII allows people who have tried at least two oral antidepressants to use the spray on its own – without the need for more ...

People with treatment-resistant depression can now take Spravato's ketamine-derived nasal spray as a standalone treatment.

The Food and Drug Administration (FDA) recently approved the nasal spray Spravato for the treatment of major depression in ...

Here's what MDs want you to know about Spravato, the latest FDA-approved standalone nasal spray for depression.

Johnson & Johnson has announced the FDA’s approval of a first-of-its-kind, esketamine nasal spray called Spravato for the ...

Johnson & Johnson's ketamine-derived nasal spray has been approved as a standalone treatment to fight depression for those ...

Spravato is now the first stand-alone therapy for treatment-resistant depression, for patients who haven’t responded to oral ...

The U.S. Food and Drug Administration ( FDA) has approved the use of a nasal spray as a standalone treatment for major depressive disorder, offering a new option for those struggling with ...

Dr. Syed Hussain from Trinity Health of New England discusses the latest health news from around the country and the world.

Share on Pinterest The FDA has approved an esketamine nasal spray for the treatment of depression cases that do not respond to other therapeutic approaches. Image credit: Koldunov/Getty Images.

FDA approves esketamine nasal spray as a standalone treatment for adults with treatment-resistant depression, offering rapid ...

The expanded indication allows esketamine nasal spray to be used as a standalone treatment in adults with MDD who have not ...